Latest Conference Articles

Results from a questionnaire show that individuals living with FCS prove that communication among people in similar situations can improve a patient’s quality of life.

At the NLA Scientific Sessions in Las Vegas this morning, Akcea Therapeutics, presented a poster with data from the largest burden of illness study in patients with FCS to date.

Children receiving AVXS-101 have shown such improvement that researchers are calling for an update to the CHOP-INTEND scale used to track their progress.

Patients from 2 demographically-different studies switching from interferon therapy to Aubagio reported similar improvements.

The executive vice president and chief medical officer of Biogen explained how crucial it is for potential DMTs to attacki the alpha-synuclein protein.

The director of the Sports Neurology Program at Norton Healthcare and head of the NCAA Headache Task Force discussed trends in his popularizing field.

Patients who had previously failed ≥2 preventative migraine treatments were effectively treated with galcanezumab, especially when compared to placebo.

Results from Alder Biopharmaceutical’s phase 3 study demonstrated reductions in migraine following quarterly infusions of both 100 mg and 300 mg eptinezumab versus placebo in patients with episodic migraines.

Lead author Alexander D. Rae-Grant, MD, explains the measures taken to ensure the panel got their 16-year multiple sclerosis recommendations update right.

Already tasked with a burdensome regimen of therapy for nerve damage, some patients may just be looking for simpler relief.

The American Academy of Neurology has issued 30 recommendations for clinicians regarding disease-modifying therapies for multiple sclerosis.

The investigative therapy for SMA reported various efficacy results in a phase 3 extension trial.

Among patients with MS who began ocrelizumab treatment in the open-label extension, MRI lesion activity was almost completely suppressed.

A new study finding that 50% of low income Latino patients with MS suffer from depression is coupled with recent reports on their exclusion from clinical research.

How a litany of treatment options could be just a single breakthrough drug away.

How the brain processes thought and action can be heavily influenced by the size of the network it's exposed to.

Trial results on the recently FDA-approved gammaCore device will be presented at the American Academy of Neurology (AAN) annual meeting.

The investigatory therapy for secondary progressive MS returned even more promising post hoc analysis prior to its FDA consideration.

A wrist-worn neuromodulation device delivers a nerve stimulation pattern tailored to the patient’s tremor.

The investigational therapy is first being researched for safety and dosage rates before efficacy is considered.

Study results show 30.3% of difficult to treat patients taking erenumab saw at least a 50% reduction in monthly migraine days.

Sephy Philip, PharmD, discussed the results of the ANCHOR trial, as well as the subgroup analysis.

Steve Deitelzweig, MD, discussed the real-world usage of direct-acting anticoagulants in comparison with the conventional warfarin, as well as the benefits they have shown based on a large data analysis.

Hadley Wilson, MD, spoke about the new heart failure guidelines and how the ACC is attempting to make them more technologically available, as well as the ACC's efforts to connect with cardiologists on a more worldwide scale to help improve cardiac outcomes globally.

A novel subretinal implantation of a stem cell-based bioengineered patch may restore vision or prevent further vision loss.

Justin Davies, MBBS, MRCP, PhD, discussed the cost-effectiveness analysis of the DEFINE-FLAIR trial comparing iFR and FFR for patients requiring PCI.

Incorporating underused, but available, imaging technologies like PET/CT to test for calcium in coronary arteries more precisely predicts those at risk for MI and similar threats.

While copayment reduction significantly affected clinician’s choice of medication and improved patient persistence with treatment, it did not impact clinical outcomes at 1 year.